for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Myriad Genetics, Inc.

MYGN.OQ

Latest Trade

26.33USD

Change

0.53(+2.05%)

Volume

59,203

Today's Range

25.52

 - 

26.42

52 Week Range

9.24

 - 

30.12

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
25.80
Open
25.52
Volume
59,203
3M AVG Volume
15.95
Today's High
26.42
Today's Low
25.52
52 Week High
30.12
52 Week Low
9.24
Shares Out (MIL)
75.21
Market Cap (MIL)
1,866.72
Forward P/E
-171.88
Dividend (Yield %)
--

Next Event

Q2 2021 Myriad Genetics Inc Earnings Release

Latest Developments

More

Myriad Genetics Forms Strategic Partnership With Illumina In Oncology

Myriad Genetics Provides Transformation Update

Myriad Genetics Reports Q1 Loss Per Share Of $0.20

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Myriad Genetics, Inc.

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Industry

Biotechnology & Drugs

Contact Info

320 S Wakara Way

SALT LAKE CITY, UT

84108-1214

United States

+1.801.5843600

http://www.myriad.com

Executive Leadership

S. Louise Phanstiel

Independent Chairman of the Board

Paul J. Diaz

President, Chief Executive Officer, Director

R. Bryan Riggsbee

Chief Financial Officer, Executive Vice President, Treasurer

Nicole Lambert

President of Myriad Womens Health, Oncology, and International

Mark S. Verratti

President of Myriad Neuroscience and Myriad Autoimmune

Key Stats

3.11 mean rating - 9 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.12
Price To Book (MRQ)
2.05
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
24.70
LT Debt To Equity (MRQ)
24.70
Return on Investment (TTM)
-15.37
Return on Equity (TTM)
-14.11

Latest News

Latest News

BRIEF-Myriad Announces New Studies Validating Ability Of Riskscore® Test To Modify Breast Cancer Risk Prediction

* MYRIAD ANNOUNCES NEW STUDIES VALIDATING THE ABILITY OF MYRIAD’S RISKSCORE® TEST TO MODIFY BREAST CANCER RISK PREDICTION Source text for Eikon: Further company coverage:

BRIEF-Myriad Announces Partnership With Optrahealth To Deliver An AI Based Information Tool For Hereditary Cancer Patients

* MYRIAD ANNOUNCES PARTNERSHIP WITH OPTRAHEALTH® TO DELIVER “GENE™” A NEW AI BASED INFORMATION TOOL FOR HEREDITARY CANCER PATIENTS

BRIEF-Camber Capital Management Lp Reports 5.37% Passive Stake In Myriad Genetics

* CAMBER CAPITAL MANAGEMENT LP REPORTS 5.37% PASSIVE STAKE IN MYRIAD GENETICS INC AS OF JUNE 11 - SEC FILING Source text : (https://bit.ly/2Nj9ZQf) Further company coverage:

BRIEF-Myriad Reports New Coverage Policies For Prolaris

* MYRIAD ANNOUNCES NEW FAVORABLE COVERAGE POLICIES FOR PROLARIS® FROM THREE NEW COMMERCIAL HEALTH PLANS INCLUDING MAJOR NATIONAL PROVIDER Source text for Eikon: Further company coverage:

BRIEF-Myriad Genetics Reports Publication Of Prospective Study Of Endopredict Test

* MYRIAD GENETICS ANNOUNCES PUBLICATION OF A PROSPECTIVE CLINICAL STUDY OF THE ENDOPREDICT® TEST IN WOMEN WITH EARLY-STAGE BREAST CANCER Source text for Eikon: Further company coverage:

BRIEF-Myriad Genetics - Board Approved Increase In Size Of Board To Nine Members

* MYRIAD GENETICS SAYS ON MAY 27, BOARD APPROVED INCREASE IN SIZE OF BOARD TO NINE MEMBERS FROM EIGHT - SEC FILING Source text for Eikon: [ID: https://bit.ly/3gxhGzq] Further company coverage:

BRIEF-Myriad Genetics Appoints Daniel K. Spiegelman To Board Of Directors

* MYRIAD GENETICS APPOINTS DANIEL K. SPIEGELMAN TO THE BOARD OF DIRECTORS AND ANNOUNCES UPCOMING RETIREMENT OF JOHN T. HENDERSON, M.D. Source text for Eikon: Further company coverage:

BRIEF-Cerecor And Myriad Genetics Announce That Levels Of Light, A Novel Cytokine, Were Highly Correlated With Disease Severity And Mortality In COVID-19 Ards Biomarker Study

* CERECOR AND MYRIAD GENETICS ANNOUNCE THAT LEVELS OF LIGHT, A NOVEL CYTOKINE, WERE HIGHLY CORRELATED WITH DISEASE SEVERITY AND MORTALITY IN COVID-19 ARDS BIOMARKER STUDY

BRIEF-Myriad Receives FDA Approval Of BRACAnalysis CDx As A Companion Diagnostic For Lynparza In HRR-mutated Metastatic Castration-Resistant Prostate Cancer

* MYRIAD RECEIVES FDA APPROVAL OF BRACANALYSIS CDX® AS A COMPANION DIAGNOSTIC FOR LYNPARZA® IN HRR-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results

* MYRIAD GENETICS REPORTS FISCAL THIRD-QUARTER 2020 FINANCIAL RESULTS

BRIEF-Myriad Genetics Announces Publication Of A Meta-Analysis Demonstrating The Clinical Utility Of The Genesight Psychotropic Test In People With Major Depressive Disorder

* MYRIAD GENETICS ANNOUNCES PUBLICATION OF A META-ANALYSIS DEMONSTRATING THE CLINICAL UTILITY OF THE GENESIGHT® PSYCHOTROPIC TEST IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER Source text for Eikon: Further company coverage:

BRIEF-Myriad Withdrawing Financial Guidance For FY2020 Due To Business Impact From Coronavirus Pandemic

* MYRIAD WITHDRAWING FINANCIAL GUIDANCE FOR FY2020 DUE TO BUSINESS IMPACT FROM CORONAVIRUS PANDEMIC

BRIEF-Myriad Receives Reimbursement For The Bracanalysis Diagnostic System In Japan For Patients With Breast Or Ovarian Cancer Associated With Hboc

* MYRIAD RECEIVES REIMBURSEMENT FOR THE BRACANALYSIS® DIAGNOSTIC SYSTEM IN JAPAN FOR PATIENTS WITH BREAST OR OVARIAN CANCER ASSOCIATED WITH HBOC Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Myriad Genetics - Seeks Japanese Regulatory Approval For Its Bracanalysis Diagnostic System

* MYRIAD GENETICS - SEEKS JAPANESE REGULATORY APPROVAL FOR ITS BRACANALYSIS DIAGNOSTIC SYSTEM IN PEOPLE WITH ADVANCED PANCREATIC AND PROSTATE CANCER Source text for Eikon: Further company coverage:

BRIEF-Myriad Genetics Says R. Bryan Riggsbee, Chief Financial Officer Appointed Interim President, CEO

* MYRIAD GENETICS INC - R. BRYAN RIGGSBEE, CHIEF FINANCIAL OFFICER APPOINTED INTERIM PRESIDENT AND CEO

BRIEF-Myriad Genetics Q2 Loss Per Share $0.11

* MYRIAD GENETICS REPORTS FISCAL SECOND-QUARTER 2020 FINANCIAL RESULTS

BRIEF-Myriad Announces Leadership Transition

* MYRIAD GENETICS INC - R. BRYAN RIGGSBEE, CFO , HAS BEEN APPOINTED INTERIM PRESIDENT & CEO EFFECTIVE IMMEDIATELY & TO CONTINUE TO SERVE AS CFO

BRIEF-Myriad Genetics Reports Q3 GAAP Earnings Per Share $0.16

* MYRIAD GENETICS REPORTS FISCAL THIRD-QUARTER 2018 FINANCIAL RESULTS

BRIEF-Myriad Receives Pre Market Approval For Its Bracanalysis Diagnostic System In Japan

Myriad Genetics Inc - Astrazeneca And Merck Are Seeking Approval Of Lynparza In Japan For Treating Patients With Brca :

BRIEF-Myriad Genetics Q2 Adjusted Earnings Per Share $0.31

* MYRIAD GENETICS REPORTS FISCAL SECOND-QUARTER 2018 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up